Is Wegovy on the PBS in Australia? 2026 Status
Is Wegovy on the PBS in Australia? 2026 Listing Status, Criteria and Cost Guide
TL;DR
Wegovy is not yet listed on the PBS in Australia. The Pharmaceutical Benefits Advisory Committee recommended a PBS listing for people with established cardiovascular disease and obesity on 16 January 2026, but price negotiations between the government and Novo Nordisk are still underway as of August 2026. Once listed, PBS patients would pay a maximum of 25 dollars per script, or 7.70 dollars with a concession card. Until then, Wegovy costs 350 to 500 dollars a month on a private prescription.
This article is general information only and is not medical advice. Eligibility for Wegovy, whether privately funded or through a future PBS listing, is determined by a registered doctor based on individual assessment. Pricing and PBS listing details reflect publicly available government information as at 1 August 2026 and are subject to change.
Is Wegovy on the PBS in Australia is the exact question thousands of Australians have typed into Google since the Pharmaceutical Benefits Advisory Committee handed down its recommendation in January 2026. The short answer is not yet.
A positive recommendation from the Pharmaceutical Benefits Advisory Committee is a required step toward a Pharmaceutical Benefits Scheme listing. It is not the same as an actual listing. Wegovy remains available only on private prescription in Australia while the government and the medicine's sponsor, Novo Nordisk Pharmaceuticals, negotiate a subsidised price.
This guide sets out exactly where the process stands, who is expected to qualify once a listing is confirmed, what Wegovy costs now, and what it should cost afterward. HolisticChem is a compounding and telehealth pharmacy in Bayswater, Victoria that dispenses Wegovy under medical supervision and can talk you through your options while the Pharmaceutical Benefits Scheme process continues.
Is Wegovy on the PBS in Australia Right Now?
No, Wegovy is not yet listed on the PBS in Australia. The government's Pharmaceutical Benefits Scheme medicine status page confirms that the Pharmaceutical Benefits Advisory Committee recommended a listing on 16 January 2026, but government processes and price negotiations with sponsor Novo Nordisk had not yet commenced as at 1 August 2026.
This information comes directly from the Pharmaceutical Benefits Scheme medicine status page for semaglutide, the active ingredient in Wegovy, which the Australian Government Department of Health and Aged Care updates as each stage of the listing process is completed. As at 1 August 2026, the page shows that documentation has been lodged but not yet formally accepted, and that the agreement to listing arrangements and government sign-off stages have not yet started.
What Did the PBAC Recommend for Wegovy?
The Pharmaceutical Benefits Advisory Committee recommended semaglutide, sold under the brand name Wegovy, for subsidised listing after its meeting on 5 November 2025. The recommendation covers adults with established cardiovascular disease and obesity, and the outcome was published in the PBAC November 2025 recommendations.
The Pharmaceutical Benefits Advisory Committee is the independent expert body that assesses whether a medicine should be subsidised through the Pharmaceutical Benefits Scheme. Its recommendation is necessary before a listing can proceed, but the committee does not set the final price or the listing date. Novo Nordisk Pharmaceuticals, the company that submitted the application, opened a notice of intent on 20 February 2026 and lodged supporting documentation a week later, on 27 February 2026.
According to the government's own tracker, that documentation had not yet been formally accepted as complete at the time this guide was last checked. That means the remaining stages, an agreement on listing arrangements and final government approval, are still ahead.
Who Will Be Eligible for PBS Subsidised Wegovy?
Based on the Pharmaceutical Benefits Advisory Committee recommendation and public statements from Health Minister Mark Butler, PBS subsidised Wegovy is expected to be limited to adults who have already had a heart attack, a stroke, or symptomatic peripheral arterial disease, and who also have a body mass index of 35 or higher, or 32.5 or higher for people of Aboriginal, Torres Strait Islander, or Asian background.
These criteria are not final until the listing is confirmed, so treat them as the expected framework rather than a guarantee. Diabetes Australia and Diabetes Victoria have both reported the same cardiovascular disease and body mass index thresholds in their coverage of the announcement. A doctor will always make the final call on eligibility once a formal listing and its authority requirements are published.
Wegovy on the PBS is being positioned as a medicine for people with obesity and existing heart disease, not as a general weight loss subsidy. Anyone who wants to use Wegovy for weight management without a qualifying cardiovascular history will likely continue paying privately even after the listing takes effect.
What Will Wegovy Cost Once It Is Listed on the PBS?
Once Wegovy is listed on the PBS, eligible patients will pay the standard PBS patient contribution, capped at 25 dollars per script for general patients or 7.70 dollars for concession card holders, both current 2026 rates set by the Australian Government Department of Health, Disability and Ageing.
These figures are the standard PBS copayment amounts that apply to every subsidised medicine, not a Wegovy specific price. The general copayment dropped from 31.60 dollars to 25.00 dollars from 1 January 2026 under the government's cheaper medicines policy, and the concession rate of 7.70 dollars is locked in until 2029.
How Much Does Wegovy Cost in Australia Right Now?
Without PBS subsidy, Wegovy currently costs between 350 and 500 dollars a month in Australia at the standard 2.4 milligram maintenance dose on a private prescription. Lower starting doses during the first few months of treatment typically cost less, from around 180 to 290 dollars a month.
HolisticChem's dedicated pricing guide, the Wegovy Australia Cost guide, breaks down the price at every dose stage along with how to get a private script through our telehealth doctors. If budget is the main barrier, ask our pharmacists about dose timing and whether Contrave or another option suits your situation better while you wait for the PBS process to finish.
When Will Wegovy Actually Be Listed on the PBS?
There is no confirmed listing date for Wegovy on the PBS as at August 2026. Two stages remain incomplete on the government's own tracker, agreement on listing arrangements and final government processes, and neither has a published timeframe.
Health Minister Mark Butler has publicly committed to finalising a Wegovy listing and has named the cardiovascular disease and body mass index criteria the government intends to apply. A public commitment is not the same as a signed agreement, and price negotiations with Novo Nordisk Pharmaceuticals can take months even after a positive PBAC recommendation. The safest approach is to check the PBS medicine status page directly for updates rather than relying on a predicted date from news coverage.
How to Access Wegovy Through HolisticChem While You Wait
HolisticChem dispenses Wegovy on private prescription now, through a medically supervised weight loss program that includes an online doctor consultation, a personalised treatment plan, and home delivery across Australia.
Our pharmacists and doctors work together so you are not left managing a new medicine on your own. You book a consultation through our online booking system, a doctor reviews whether Wegovy or another option such as Ozempic or Contrave suits your health history, and if appropriate, your prescription is dispensed from our Bayswater pharmacy and shipped by Australia Post Express.
If your circumstances match the cardiovascular disease and body mass index criteria the government has flagged, our team can also help you understand what changes for you once a PBS listing is confirmed.
Frequently Asked Questions
Is Wegovy the same medicine as Ozempic?
Wegovy and Ozempic both contain the active ingredient semaglutide, but they are approved for different uses and doses. Ozempic is approved and already listed on the PBS for type 2 diabetes. Wegovy is approved for weight management and is the version currently under PBS review for people with obesity and established cardiovascular disease.
Will Wegovy be completely free under the PBS?
No. Even once Wegovy is listed, patients still pay the standard PBS patient contribution, up to 25 dollars per script for general patients or 7.70 dollars for concession card holders. The PBS lowers the price significantly, but it does not make the medicine free.
What body mass index do you need to qualify for PBS subsidised Wegovy?
Based on the current recommendation, a body mass index of 35 or higher is expected, or 32.5 or higher for people of Aboriginal, Torres Strait Islander, or Asian background, combined with a history of heart attack, stroke, or symptomatic peripheral arterial disease. These thresholds are not finalised until the listing is confirmed.
Can I get Wegovy on the PBS for weight loss alone, without heart disease?
Not under the current PBAC recommendation. The listing is designed for people with obesity and established cardiovascular disease, not for weight loss on its own. Anyone without a qualifying cardiovascular history will likely continue to pay privately even after the listing takes effect.
Where can I check the official status of the Wegovy PBS listing?
The Australian Government's Pharmaceutical Benefits Scheme medicine status page tracks the listing progress for semaglutide, including PBAC outcomes, documentation stages, and whether a final listing has occurred. This is the most reliable source for updates, ahead of general health news coverage.
Conclusion
Wegovy is not yet on the PBS in Australia, but the process is further along than it was a year ago. The Pharmaceutical Benefits Advisory Committee has recommended a listing; the expected eligibility criteria are public; and the remaining steps are price negotiation and government sign-off.
Three things to remember: check the PBS medicine status page for the latest official update rather than a news headline, budget for 350 to 500 dollars a month if you start Wegovy privately now, and speak with a doctor about whether your health history is likely to meet the expected cardiovascular disease and body mass index criteria.
HolisticChem can help you start Wegovy on private prescription today, or answer your questions about the PBS process while you decide. Call our Bayswater pharmacy on 03 8204 6600 or book an online consultation through our weight loss program to get started.